Phase 2 Trial Planned for FHL-301 in Treating Early Stage Parkinson’s
Forest Hills Lab announced that it has U.S. Food and Drug Administration (FDA) permission to open a Phase 2 trial into…
Articles by Patricia Inácio, PhD
FDA Places DA01, Cell Therapy for Advanced Parkinson’s, on Fast Track
The U.S. Food and Drug Administration (FDA) has given fast track designation to the investigational cell therapy DA01, now in a clinical…
Ipsen Acquires Global Rights to Mesdopetam
Ipsen has entered into an exclusive worldwide licensing agreement with Integrative Research Laboratories (IRLAB) to develop and commercialize…
$1.9M Grant Aims to Revolutionize Parkinson’s Therapy Development
A £1.375 ($1.9) million grant from the Edmond J. Safra Foundation will support a pioneering clinical trial aimed at speeding the development…
FDA OKs Second Trial to Test Effects of Stem-cell Infusions
The U.S. Food and Drug Administration (FDA) has approved a Phase 3 trial to test multiple infusions of fat-derived mesenchymal…
First Patient Treated in Study Testing Aleva’s directSTIM DBS System
Aleva Neurotherapeutic’s innovative directional deep brain stimulation (DBS) system — called directSTIM — for Parkinson’s disease has been…
Swedish Biobank Promises to Help Unveil Genetics of Parkinson’s
A new biobank in Sweden, containing blood samples from patients with Parkinson’s disease and age- and sex-matched healthy people…
Nasal Gel Enhances Levodopa Delivery to Brain in Preclinical Study
Levodopa, a standard treatment for Parkinson’s disease, reached the brain faster when given as a gel into the…
Investigational Immunotherapy ImmCelz Shows Promise in Mice
Creative Medical Technology Holdings has extended the applications of its investigational “regenerative immunotherapy” ImmCelz to include Parkinson’s disease, after seeing…
NEA Funds Artist’s Exhibition of Father’s Parkinson’s Journey
The Parkinson’s Foundation has received a $30,000 grant from the National Endowment for the Arts (NEA) to support a…